SEC Form 4 · accession 0001193125-26-396935
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ali Behbahani
Director
Period of report
Aug 6, 2025
Accepted (ET)
Sep 21, 2026 · 6:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Aug 6, 2025 | J | 60 | $0.00 | A | 316 | D | |
| Common SharesF3 | Aug 6, 2025 | J | 15 | $0.00 | A | 29 | I | See Note 3 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1NEA Partners 15, L.P. ("NEA Partners 15") made a pro rata distribution for no consideration of Common Shares of the Issuer to its limited partners on August 6, 2025. The Reporting Person received 60 Common Shares of the Issuer in the distribution by NEA Partners 15 on August 6, 2025.
- F2The Ali Behbahani Revocable Trust Dated June 26, 2015 (the "Behbahani Trust") received 15 Common Shares of the Issuer in the distribution by NEA Partners 15 on August 6, 2025.
- F3The Reporting Person is the trustee of the Behbahani Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, of such portion of the Common Shares of the Issuer held by the Behbahani Trust in which the Reporting Person has no pecuniary interest.